Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Taskuya Furuta"'
Autor:
Mitsutoshi Nakada, Guangtao Zhang, Shingo Tanaka, Taskuya Furuta, Hemragul Sabit, Jiakang Zhang, Shabierjiang Jiapaer, Yu Dong, Tomohiro Kitabayashi
Publikováno v:
Neuro Oncol
BACKGROUND Glioblastoma (GBM) represents the most aggressive and frequent type of primary malignant brain tumors with a dismal clinical outcome. Though adjuvant temozolomide (TMZ) chemotherapy followed by surgical resection can extend patient`s post-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5b91396cf8d72bc4b0bd5b13d767000
https://europepmc.org/articles/PMC6847336/
https://europepmc.org/articles/PMC6847336/
Autor:
Yasuo Uchida, Sho Tamai, Sumio Ohtsuki, Jiakang Zhang, Shabierjiang Jiapaer, Hemragul Sabit, Mitsutoshi Nakada, Taskuya Furuta, Tetsuya Terasaki
Publikováno v:
Neuro Oncol
BACKGROUND Among potential glioblastoma (GBM) blood biomarkers that we identified recently, we focused on gelsolin (GSN), a key regulator of actin filament disassembly. GSN was significantly lower in the blood of patients with GBM than in that of hea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::161d54dcd652a94c1fa2bacfb82c6ca7
https://europepmc.org/articles/PMC6847733/
https://europepmc.org/articles/PMC6847733/
Autor:
Hemragul Sabit, Yu Dong, Tomohiro Kitabayashi, Taskuya Furuta, Mitsutoshi Nakada, Shabierjiang Jiapaer, Atsushi Hirao
Publikováno v:
Neuro-Oncology. 19:iii28-iii28
Introduction: Glioma stem cell (GSC)-targeted therapy is a promising treatment for patient with glioblastoma (GBM). However, none of the drugs that restrain the signaling pathways which are essential for GSC maintenance has been put to clinical use.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36b8394ffdf901f870bc7e92c04ff354
https://doi.org/10.1093/neuonc/nox036.098
https://doi.org/10.1093/neuonc/nox036.098
